Guidelines

P14 PRELIMINARY EVALUATION OF ADAMTS-13 ANTIBODY TESTING

November 2018
P15 OPTIMISATION OF THE CALIBRATION CURVE FOR THE ACCURATE MEASUREMENT OF LOW FVIII LEVELS WITH ONE-STAGE ASSAYS

November 2018
P16 HOW TO DEAL WITH SAMPLES WITH ERRORS ON APTT, PT AND FIBRINOGEN DUE TO OPTICAL CLOT DETECTION?

November 2018
P17 ESTABLISHMENT OF A THROMBIN GENERATION THRESHOLD IN SEVERE HAEMOPHILIAC PATIENTS UNDER PROPHYLAXIS TO FURTHER DETERMINE AN ADDED VALUE OF THIS TEST IN THE PERSONALIZED TREATMENT: A PILOT STUDY

November 2018
P18 EVALUATION OF THE TAV8® (STAGO) AGGREGOMETER IN THE CLINICAL LABORATORY

November 2018
P19 EVALUATION OF AN AUTOMATED LIGHT TRANSMISSION AGGREGOMETRY

November 2018
P20 EVALUATION OF THE NEW KIT STA-VWF RCO (STAGO) MEASURING WILLEBRAND FACTOR ACTIVITY AND COMPARISON WITH TWO SIEMENS KITS: BC VON WILLEBRAND REAGENT AND INNOVANCE VW ACTIVITY

November 2018
P21 A NOVEL ADAMTS13 CONFORMATION ELISA SHOWS CONFORMATIONAL ACTIVATION OF RAT ADAMTS13 WITH EXPOSURE OF CRYPTIC EPITOPES IN VITRO

November 2018
P22 ANTI-CUB1 OR ANTI-SPACER ANTIBODIES THAT INCREASE ADAMTS13 ACTIVITY ACT BY ALLOSTERICALLY ENHANCING METALLOPROTEASE DOMAIN FUNCTION

November 2018
P23 BETRIXABAN: IMPACT ON ROUTINE AND SPECIFIC COAGULATION ASSAYS – A PRACTICAL LABORATORY GUIDE

November 2018

Top